about
B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized InflammationTherapeutic decisions in multiple sclerosis: moving beyond efficacyMyeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice.An updated histological classification system for multiple sclerosis lesions.Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis.Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosisPeroxisome proliferator-activated receptor (PPAR)α and -γ regulate IFNγ and IL-17A production by human T cells in a sex-specific way.Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.Dual role of ALCAM in neuroinflammation and blood-brain barrier homeostasis.Glial influence on the blood brain barrier.Update on treatments in multiple sclerosis.Glial regulation of the blood-brain barrier in health and disease.Glial influences on BBB functions and molecular players in immune cell trafficking.Secondary Progression in Multiple Sclerosis: Neuronal Exhaustion or Distinct Pathology?Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.Laquinimod enhances central nervous system barrier functions.Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.Contribution of different relapse phenotypes to disability in multiple sclerosis.Melanoma cell adhesion molecule-positive CD8 T lymphocytes mediate central nervous system inflammation.Extracellular matrix metalloproteinase inducer shows active perivascular cuffs in multiple sclerosis.IL-1β enables CNS access to CCR2hi monocytes and the generation of pathogenic cells through GM-CSF released by CNS endothelial cells.Targeting the GM-CSF receptor for the treatment of CNS autoimmunity.USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.Death receptor expression and function at the human blood brain barrier.Melanoma cell adhesion molecule identifies encephalitogenic T lymphocytes and promotes their recruitment to the central nervous system.Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions.Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.Role of Ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions.Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal.Production of IL-27 in multiple sclerosis lesions by astrocytes and myeloid cells: Modulation of local immune responses.Defining reliable disability outcomes in multiple sclerosis.NKG2D-mediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis.Erratum: USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation.EphrinB1 and EphrinB2 regulate T cell chemotaxis and migration in experimental autoimmune encephalomyelitis and multiple sclerosis.An optimized method to process mouse CNS to simultaneously analyze neural cells and leukocytes by flow cytometryThe blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cellsActivated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous systemIsolation of human brain endothelial cells and characterization of lipid raft-associated proteins by mass spectroscopyFirategrast: natalizumab in a pill?
P50
Q26770852-BC1FBDFE-AA11-45F4-A59F-0EEE19D38C9DQ28541039-A823476D-EE00-4519-B8B4-F1DD032A419DQ30763241-C8486DEF-EA9E-4532-887D-909BC3D16DB9Q34547552-BE6B16D1-66F3-4276-8FD6-7D76C03189E8Q34666702-457124A6-A57B-47F1-913B-DCD80E6D39C8Q35586871-73D7E55E-3799-433C-BBAD-3B9A9A3F4A5CQ36066219-110AB004-A4DE-42A0-A212-AAB4E8F3183FQ36984429-EE01244F-B1EB-4EC0-B3FD-E5FCC8FA6DB9Q37612597-00479080-56A5-42CA-9ECE-2CEDB7C0AFA6Q38152380-E1775F34-A445-4831-BB21-D1F41BC00FE3Q38392347-81189B6A-A7FC-47F3-B441-5B50673061EBQ38561270-6E7C25B2-D734-404C-BAB6-3AFC106AD52AQ38603665-E60CFB7B-3FFB-4256-AC20-B860F97F3830Q38778433-C643A767-B851-4831-990D-9F1F774BA0F2Q38850911-3996F431-8A67-475A-9368-5C7E671DEC5FQ38943274-25101243-C189-4B02-B0DC-A3BCC3E752EBQ40302214-D31BEB87-77DF-4BDD-AB27-F183722B6911Q40724148-60296129-B1BF-4FBF-A54E-080333FE356BQ41079121-104D5199-BF10-42E5-B30B-E0559101CF30Q44029123-FA7B62FC-6FB7-42C6-9141-879C5F53FB01Q47846333-05BF1E6B-E621-4F98-B271-78D40165383EQ47854294-DBC92C85-7D6F-4489-A103-99740B5A9D80Q47974546-1AD72423-9955-40F4-B42D-0BF18D948255Q48224302-EB80D902-0192-43B7-85D0-0E0124CB9CC0Q48378104-2AA15EDF-64AB-4598-B6FB-1946FFC06018Q48435937-1E7530B1-ADB0-479B-BF86-FAF52A672D9DQ48439984-951475FB-6F7D-4559-AF54-CE53EAB6A3D8Q48607199-C746957C-A2FC-495B-AC12-2B0D6D9922ADQ48786036-C379320B-217C-407A-9D14-1F6843C20A21Q52142630-0D23C8BF-2A1E-4D9F-8E66-4FBA04C964F2Q52145132-37B2A598-1E17-4290-87F6-ABB19BDF0108Q52149517-A6D2364F-CE95-4234-9877-4E33A1B559BCQ52576677-D93945CB-68D1-4680-8C29-C10B9AF0A3B2Q54561330-500F6FB6-4627-4CE1-94CC-5B21A075E608Q54651547-C06524AA-77AF-4CBD-B46F-587607FD680BQ60446133-C5F24419-92BD-4FB6-9CD0-220ECABF880DQ60446151-6869AEC9-A9D6-4224-A1CD-FDAD51D1F521Q60446155-0A5325CC-3FD5-493E-8269-764DB666C0F3Q82478004-8AA3F733-FDA1-4411-9457-F250284E3950Q83193034-2C4AC848-C4BA-43E1-9CE4-1BE852E8EF47
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexandre Prat
@ast
Alexandre Prat
@en
Alexandre Prat
@es
Alexandre Prat
@nl
Alexandre Prat
@sl
type
label
Alexandre Prat
@ast
Alexandre Prat
@en
Alexandre Prat
@es
Alexandre Prat
@nl
Alexandre Prat
@sl
prefLabel
Alexandre Prat
@ast
Alexandre Prat
@en
Alexandre Prat
@es
Alexandre Prat
@nl
Alexandre Prat
@sl
P108
P106
P31
P496
0000-0001-6188-0580